Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of insulin glargine U300 versus Lantus in type 2 diabetes on basal-bolus therapy
NL-OMON39048Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing HOE901-U300 plus mealtime insulin with Lantus plus mealtime insulin (2 arms). Primary endpoint: Change in HbA1c from baseline to week 24. Started Feb 2012; status: active, not recruiting.
02
Drugs
insulin glargineinsulin glargine U300
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON39048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39048.